High Court Denies Bid To Review Neurontin RICO Rulings

By Gavin Broady (December 9, 2013, 12:47 PM EST) -- The U.S. Supreme Court on Monday denied Pfizer Inc.'s bid to rehear three First Circuit rulings related to its allegedly deceptive marketing of Neurontin, allowing to stand the First Circuit's determination that resulting off-label prescriptions harmed Kaiser Foundation Health Plan Inc. and others.

That ruling affirmed a $142 million jury verdict in favor of HMO operator Kaiser, and the high court's denial of certiorari means the company is now facing the possibility of two further trials against Aetna Inc. and Harden Manufacturing Corp. All three suits involve allegations Pfizer fraudulently marketed the anxiety disorder drug as having off-label benefits that ultimately...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!